Industry sponsorship and the publication of small clinical trials of off-label uses for novel anticonvulsants.

被引：0

|

作者：

Barron, JS ^{[1
]}

Finucane, TE ^{[1
]}

机构：

[1] Johns Hopkins Univ, Div Geriatr Med & Gerontol, Baltimore, MD USA

来源：

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2005年 / 53卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

引用

收藏

页码：S213 / S214

页数：2

相关论文

共 34 条

[31] Addressing the "What do we have to lose? Just give the drug" rationale: making the case for clinical trials and against off-label use in COVID-19
Ramnath, Venktesh R.
Zar, Heather J.
Malhotra, Atul
JOURNAL OF THORACIC DISEASE, 2020, 12 (06) : 3031 - 3034
[32] Current status of gemcitabine (Gemzar) and MTA in the treatment of non-small cell lung cancer - Off-label uses of commercial products or investigational uses not cleared for marketing that are referenced by the authors in this journal supplement and that relate to Eli Lilly and Company, its subsidiaries or business partners
不详
SEMINARS IN ONCOLOGY, 1999, 26 (01) : 38 - 38
[33] Clinical outcomes following drug-eluting versus bare metal stent implantation for lesion subsets excluded from pivotal clinical trials: Findings from the GHOST study (Guthrie Health System off-label StenT study)
Harjai, Kishore J.
Orshaw, Pamela
Shenoy, Chetan
Acharji, Subasit
Sporn, Daniel
Aboufares, Ali
Stapleton, Dwight
JOURNAL OF INTERVENTIONAL CARDIOLOGY, 2008, 21 (04) : 315 - 324
[34] Clinical outcomes following drug-eluting versus bare metal stent implantation for lesion subsets excluded from pivotal clinical trials: Findings from the GHOST study (guthrie health system off-label StenT study) (vol 4, pg 315, 2008)
Harjai, Kishore J.
Orshaw, Pamela
Shenoy, Chetan
Acharji, Subasit
Sporn, Daniel
Aboufares, Ali
Stapleton, Dwight
JOURNAL OF INTERVENTIONAL CARDIOLOGY, 2008, 21 (05) : 441 - 441

← 1 2 3 4 →